临床肝胆病杂志Issue(1)：169-173,5.DOI:10.3969/j.issn.1001-5256.2016.01.037
无干扰素抗HCV方案的研究进展
Research progress in anti-HCV therapeutic regimens without interferon
摘要
Abstract
There are about 150 million people around the world with chronic hepatitis C virus (HCV)infection currently,of whom 20%will ultimately progress to cirrhosis and eventually die of end-stage liver disease and hepatocellular carcinoma.Interferon (IFN)has long been recognized as the cornerstone of the treatment of chronic hepatitis C because of its role in sustained virologic response and prevention of disease progression.However,it has limited efficacy and multiple adverse effects.In recent years,direct-acting antiviral agents (DAAs) have shown good efficacy.This review summarizes the recent advances in IFN-free anti-HCV therapeutic regimens based on DAAs.We believe that,with the emergence of DAAs,IFN-free therapies will develop rapidly and display better prospects.关键词
肝炎,丙型,慢性/抗病毒药/蛋白酶抑制药/综述Key words
hepatitis C,chronic/antiviral agents/protease inhibitors/review分类
医药卫生引用本文复制引用
李强,黄玉仙,陈良..无干扰素抗HCV方案的研究进展[J].临床肝胆病杂志,2016,(1):169-173,5.基金项目
上海市科委“科技创新行动计划”医学与农业领域重点项目（13401902100）；上海市卫生局临床医学应用研究项目 （）
